PL3054926T3 - Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu - Google Patents

Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu

Info

Publication number
PL3054926T3
PL3054926T3 PL14786421T PL14786421T PL3054926T3 PL 3054926 T3 PL3054926 T3 PL 3054926T3 PL 14786421 T PL14786421 T PL 14786421T PL 14786421 T PL14786421 T PL 14786421T PL 3054926 T3 PL3054926 T3 PL 3054926T3
Authority
PL
Poland
Prior art keywords
cobicistat
atazanavir
treatment formulation
hiv treatment
hiv
Prior art date
Application number
PL14786421T
Other languages
English (en)
Inventor
Otilia May Yue Koo
Faranak Nikfar
Jing Tao
Niranjan Kumar KOTTALA
Sailesh A. Varia
Original Assignee
Bristol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51743576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3054926(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland filed Critical Bristol-Myers Squibb Holdings Ireland
Publication of PL3054926T3 publication Critical patent/PL3054926T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14786421T 2013-10-07 2014-10-06 Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu PL3054926T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887574P 2013-10-07 2013-10-07
EP14786421.9A EP3054926B1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat
PCT/US2014/059310 WO2015054133A1 (en) 2013-10-07 2014-10-06 Hiv treatment formulation of atazanavir and cobicistat

Publications (1)

Publication Number Publication Date
PL3054926T3 true PL3054926T3 (pl) 2018-12-31

Family

ID=51743576

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18179796.0T PL3421033T3 (pl) 2013-10-07 2014-10-06 Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu
PL14786421T PL3054926T3 (pl) 2013-10-07 2014-10-06 Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18179796.0T PL3421033T3 (pl) 2013-10-07 2014-10-06 Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu

Country Status (28)

Country Link
US (2) US20160038502A1 (pl)
EP (2) EP3421033B1 (pl)
JP (2) JP6574415B2 (pl)
KR (1) KR102286386B1 (pl)
CN (1) CN106029058A (pl)
AU (1) AU2014332200B2 (pl)
BR (1) BR112016007526A8 (pl)
CA (1) CA2926650A1 (pl)
CL (1) CL2016000787A1 (pl)
CY (1) CY1121105T1 (pl)
DK (2) DK3054926T3 (pl)
EA (1) EA031172B1 (pl)
ES (2) ES2693580T3 (pl)
HR (2) HRP20221126T1 (pl)
HU (1) HUE059757T2 (pl)
IL (1) IL244881B (pl)
LT (2) LT3054926T (pl)
MX (1) MX368268B (pl)
MY (1) MY178960A (pl)
PE (1) PE20160596A1 (pl)
PL (2) PL3421033T3 (pl)
PT (2) PT3054926T (pl)
RS (2) RS63570B1 (pl)
SA (1) SA516370891B1 (pl)
SG (1) SG11201602501VA (pl)
SI (2) SI3421033T1 (pl)
SM (2) SMT202200373T1 (pl)
WO (1) WO2015054133A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
PL3421033T3 (pl) * 2013-10-07 2022-10-03 Bristol-Myers Squibb Holdings Ireland Unlimited Company Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu
HK1258284A1 (zh) 2015-10-30 2019-11-08 癌症预防制药股份有限公司 依氟鸟氨酸和舒林酸，固定剂量的组合制剂
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
WO2018029565A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) * 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
AU2007302586B2 (en) * 2006-09-25 2013-06-27 Archer-Daniels-Midland Company Superabsorbent surface-treated carboxyalkylated polysaccharides and process for producing same
HUE029842T2 (en) 2007-02-23 2017-04-28 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
JP2010530889A (ja) * 2007-06-22 2010-09-16 ブリストル−マイヤーズ スクイブ カンパニー アタザナビルを含む錠剤組成物
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2009084086A1 (ja) * 2007-12-27 2009-07-09 Fujitsu Limited 通信システム，回線提供装置および通信方法
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
PL3421033T3 (pl) * 2013-10-07 2022-10-03 Bristol-Myers Squibb Holdings Ireland Unlimited Company Leczenie zakażenia wirusem hiv formulacją atazanawiru i kobicystatu

Also Published As

Publication number Publication date
MX368268B (es) 2019-09-26
CN106029058A (zh) 2016-10-12
SA516370891B1 (ar) 2018-08-08
MX2016004078A (es) 2016-06-06
JP6574415B2 (ja) 2019-09-11
EP3054926A1 (en) 2016-08-17
SI3054926T1 (sl) 2018-10-30
IL244881B (en) 2021-12-01
ES2927484T3 (es) 2022-11-07
EP3421033B1 (en) 2022-07-27
KR102286386B1 (ko) 2021-08-05
PT3421033T (pt) 2022-09-23
HUE059757T2 (hu) 2023-01-28
MY178960A (en) 2020-10-26
AU2014332200B2 (en) 2018-10-04
PT3054926T (pt) 2018-10-26
JP2016532649A (ja) 2016-10-20
DK3421033T3 (da) 2022-10-10
PE20160596A1 (es) 2016-06-15
AU2014332200A1 (en) 2016-05-19
HRP20221126T1 (hr) 2022-11-25
BR112016007526A2 (pt) 2017-08-01
EP3421033A1 (en) 2019-01-02
LT3054926T (lt) 2018-11-12
SMT201800507T1 (it) 2018-11-09
WO2015054133A1 (en) 2015-04-16
HRP20181582T1 (hr) 2018-11-30
SI3421033T1 (sl) 2022-11-30
CA2926650A1 (en) 2015-04-16
EP3054926B1 (en) 2018-07-25
EA201690594A1 (ru) 2016-09-30
SG11201602501VA (en) 2016-04-28
CY1121105T1 (el) 2019-12-11
SMT202200373T1 (it) 2022-11-18
US20190358240A1 (en) 2019-11-28
RS57882B1 (sr) 2019-01-31
JP2019011334A (ja) 2019-01-24
RS63570B1 (sr) 2022-10-31
PL3421033T3 (pl) 2022-10-03
BR112016007526A8 (pt) 2020-03-03
ES2693580T3 (es) 2018-12-12
DK3054926T3 (en) 2018-10-29
US20160038502A1 (en) 2016-02-11
CL2016000787A1 (es) 2016-11-25
LT3421033T (lt) 2022-11-10
EA031172B1 (ru) 2018-11-30
IL244881A0 (en) 2016-05-31
KR20160060764A (ko) 2016-05-30

Similar Documents

Publication Publication Date Title
ZA201601344B (en) Methods and compositions for rna-guided treatment of hiv infection
LT3019503T (lt) Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
SMT201700525T1 (it) Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
IL240213A0 (en) Sulfamoyl-arylamides and their use as drugs for the treatment of jaundice b
IL244881B (en) A formulation of atazanavir and cobicistat for the treatment of AIDS
HUE067381T2 (hu) L-4-klórkinurenin dózisformái és terápiás alkalmazásai
IL243486A0 (en) Treatment of multiple sclerosis using a combination of laquinimod and flupirtine
AU2014353885B2 (en) Prevention and treatment of toxicosis
EP2945703A4 (en) ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF
EP2968127A4 (en) LOW GLYCEROL PREPARATIONS FOR HIV TREATMENT AND PREVENTION
PL3166642T3 (pl) Transdermalne preparaty pergolidu i ich zastosowanie
GB201309431D0 (en) Treatment and prevention of malaria
AU2013101402A4 (en) Timber treatment formulations and methods of use
AU2013904517A0 (en) Prevention and treatment of toxicosis